Oncopeptides AB (LTS:0RN4) Cyclically Adjusted FCF per Share: kr-6.43 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RN4 Oncopeptides AB LTS:0RN4
45 GF Score
Price kr1.61
GF Value kr4.41
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Cyclically Adjusted FCF per Share?

Oncopeptides AB LTS:0RN4 45 Cyclically Adjusted FCF per Share is kr-6.43 as of Mar. 2026. GuruFocus rates LTS:0RN4 with a GF Score™ of 45/100 and a GF Value™ of kr4.41 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Oncopeptides AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.170. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-6.43 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-19), Oncopeptides AB's current stock price is kr1.609. Oncopeptides AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-6.43. Oncopeptides AB's Cyclically Adjusted Price-to-FCF of today is .


Oncopeptides AB  (LTS:0RN4) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Oncopeptides AB Cyclically Adjusted FCF per Share Related Terms


Oncopeptides AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB Cyclically Adjusted FCF per Share Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -6.90

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -6.81 -6.90 -6.43

LTS:0RN4 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Oncopeptides AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Cyclically Adjusted Price-to-FCF falls into.


LTS:0RN4
45GF Score
Oncopeptides AB LTS:0RN4
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncopeptides AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.17/133.5600*133.5600
=-0.170

Current CPI (Mar. 2026) = 133.5600.

Oncopeptides AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.319 101.019 -0.422
201609 -0.445 101.138 -0.588
201612 -0.724 102.022 -0.948
201703 -1.305 102.022 -1.708
201706 -1.147 102.752 -1.491
201709 -1.377 103.279 -1.781
201712 -0.697 103.793 -0.897
201803 -0.646 103.962 -0.830
201806 -1.302 104.875 -1.658
201809 -1.360 105.679 -1.719
201812 -1.565 105.912 -1.974
201903 -1.853 105.886 -2.337
201906 -1.596 106.742 -1.997
201909 -2.450 107.214 -3.052
201912 -2.431 107.766 -3.013
202003 -3.581 106.563 -4.488
202006 -3.066 107.498 -3.809
202009 -3.218 107.635 -3.993
202012 -3.335 108.296 -4.113
202103 -3.604 108.360 -4.442
202106 -2.916 108.928 -3.575
202109 -2.834 110.338 -3.430
202112 -3.397 112.486 -4.033
202203 -1.398 114.825 -1.626
202206 -0.887 118.384 -1.001
202209 -0.508 122.296 -0.555
202212 -0.544 126.365 -0.575
202303 -0.627 127.042 -0.659
202306 -0.757 129.407 -0.781
202309 -0.571 130.224 -0.586
202312 -0.546 131.912 -0.553
202403 -0.664 132.205 -0.671
202406 0.051 132.716 0.051
202409 -0.593 132.304 -0.599
202412 -0.315 132.987 -0.316
202503 -0.327 132.825 -0.329
202506 -0.231 133.699 -0.231
202509 -0.141 133.480 -0.141
202512 -0.217 133.390 -0.217
202603 -0.170 133.560 -0.170

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-6.43 mean?
Oncopeptides AB (LTS:0RN4) has a Cyclically Adjusted FCF per Share of kr-6.43 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Cyclically Adjusted FCF per Share too high?
Oncopeptides AB's current Cyclically Adjusted FCF per Share is kr-6.43. Overall, Oncopeptides AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Oncopeptides AB's Cyclically Adjusted FCF per Share of kr-6.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Cyclically Adjusted FCF per Share is kr-6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (LTS:0RN4) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.41, compared to a current price of kr1.61 — trading 63.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-6.43. Oncopeptides AB's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Oncopeptides AB (LTS:0RN4), the current Cyclically Adjusted FCF per Share is kr-6.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.61 is trading 63.5% below its estimated GF Value™ of kr4.41. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for LTS:0RN4:

  • Cyclically Adjusted FCF per Share: kr-6.43
  • GF Value™: kr4.41 vs. price of kr1.61 (63.5% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
45GF Score

Get the complete analysis for LTS:0RN4

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.61
Price
kr4.41
GF Value